文献速递妇科

晚期高级别浆液性卵巢癌延迟减瘤术中化疗中断超过10周与更差预后相关

Prolonged interruption of chemotherapy in patients undergoing delayed debulking surgery for advanced high grade serous ovarian cancer is associated with a worse prognosis.
PubMed 文献 · Gynecol Oncol · 2020-04-25

该回顾性队列纳入205例FIGO III–IV期高级别浆液性卵巢癌行间歇性减瘤术患者,分析术前至术后化疗间隔与生存的关系。中位间隔63天,多因素分析显示肉眼残留病灶和化疗中断>10周与更差总生存相关,合并症和较长住院是化疗中断延长的独立预后因素。作者建议化疗中断应≤10周。

要点

  • 化疗中断>10周与更差总生存独立相关(HR 1.65,95%CI 1.201–2.290,p=0.002)。
  • 肉眼残留病灶与更差总生存相关(HR 2.280,95%CI 1.635–3.177,p≤0.001)。
  • 合并症和较长住院是化疗中断延长的独立预后因素。

核心结论

  • 为行间歇性减瘤术而中断化疗应≤10周,否则总生存显著受影响。
  • 术前合并症患者应加强围手术期支持以尽量减少化疗中断。

研究设计与样本

  • 回顾性队列研究,纳入205例FIGO III–IV期高级别浆液性卵巢癌行间歇性减瘤术患者。
  • 分析术前至术后化疗间隔与无进展生存和总生存的相关性,并行单因素和多因素分析。

主要发现

  • 术前至术后化疗中位间隔为63天。
  • 多因素分析显示肉眼残留病灶与更差总生存相关(HR 2.280,95%CI 1.635–3.177,p≤0.001)。
  • 化疗中断>10周与更差总生存相关(HR 1.65,95%CI 1.201–2.290,p=0.002)。
  • 现有合并症和较长住院是化疗中断延长的独立预后因素。

关键数值与推荐

  • 化疗中断>10周定义为预后不良因素,与更差总生存相关(HR 1.65,95%CI 1.201–2.290,p=0.002)。
  • 肉眼残留病灶与更差总生存相关(HR 2.280,95%CI 1.635–3.177,p≤0.001)。

临床怎么用

  • 对行间歇性减瘤术的高级别浆液性卵巢癌患者,应尽量将术前至术后化疗中断控制在≤10周。
  • 对术前存在合并症的患者加强围手术期支持,以减少化疗中断时间。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The current standard of care for advanced high grade serous ovarian cancer (HGSC) comprises a combination of debulking surgery and platinum-based chemotherapy given in the neoadjuvant or adjuvant setting. In the neoadjuvant setting, patients usually undergo 3 cycles of chemotherapy followed by interval cytoreductive surgery (ICS), then 3 further cycles of chemotherapy. However, the optimum timeframe to administer chemotherapy before and after ICS remains unclear. We therefore examine the survival impact of the interval between pre- and post-operative chemotherapy in patients undergoing ICS in a well-established patient cohort. Factors leading to "delays" in recommencing post-operative chemotherapy were also examined. METHODS: The study comprises of a retrospective cohort of 205 cases with FIGO stage III and IV HGSC undergoing ICS. The duration of the interval between pre-operative and post-operative chemotherapy was correlated with progression-free (PFS) and overall survival (OS). Univariate and multivariate analyses were constructed to identify factors associated with survival and prolonged chemotherapy interruption. RESULTS: The median interval between pre-operative and post-operative chemotherapy was 63 days. Multivariate analyses revealed macroscopic residual disease (HR:2.280, 95% CI:1.635-3.177, p ≤ 0.001) and interruption of chemotherapy >10 weeks (HR:1.65, 95%CI:1.201-2.290, p = 0.002) were associated with poorer OS. Existing medical comorbidities and longer hospital stay were independent prognostic factors for prolonging the chemotherapy interruption. CONCLUSION: Our study recommends that interruption to chemotherapy to allow patients to undergo ICS should be ≤10 weeks; otherwise, OS is significantly impacted. Patients with pre-existing medical comorbidities should receive additional support pre- and post-operatively to keep the chemotherapy interruption to a minimum.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Searle G, Pounds R, Phillips A, et al. Prolonged interruption of chemotherapy in patients undergoing delayed debulking surgery for advanced high grade serous ovarian cancer is associated with a worse prognosis. Gynecol Oncol. 2020. PMID: 32345546. doi:10.1016/j.ygyno.2020.04.048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。